Magnetic resonance guided SBRT reirradiation in locally recurrent prostate cancer: a multicentric retrospective analysis.
MRgRT
Prostate cancer
Radiotherapy
Reirradiation
SBRT
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
22 May 2023
22 May 2023
Historique:
received:
26
10
2022
accepted:
26
04
2023
medline:
24
5
2023
pubmed:
23
5
2023
entrez:
22
5
2023
Statut:
epublish
Résumé
Reirradiation of prostate cancer (PC) local recurrences represents an emerging challenge for current radiotherapy. In this context, stereotactic body radiation therapy (SBRT) allows the delivery of high doses, with curative intent. Magnetic Resonance guided Radiation Therapy (MRgRT) has shown promising results in terms of safety, feasibility and efficacy of delivering SBRT thanks to the enhanced soft tissue contrast and the online adaptive workflow. This multicentric retrospective analysis evaluates the feasibility and efficacy of PC reirradiation, using a 0.35 T hybrid MR delivery unit. Patients affected by local recurrences of PC and treated in five institutions between 2019 and 2022 were retrospectively collected. All patients had undergone previous Radiation Therapy (RT) in definitive or adjuvant setting. Re-treatment MRgSBRT was delivered with a total dose ranging from 25 to 40 Gy in 5 fractions. Toxicity according to CTCAE v 5.0 and treatment response were assessed at the end of the treatment and at follow-up. Eighteen patients were included in this analysis. All patients had previously undergone external beam radiation therapy (EBRT) up to a total dose of 59.36 to 80 Gy. Median cumulative biologically effective dose (BED) of SBRT re-treatment was 213,3 Gy (103,1-560), considering an α/β of 1.5. Complete response was achieved in 4 patients (22.2%). No grade ≥ 2 acute genitourinary (GU) toxicity events were recorded, while gastrointestinal (GI) acute toxicity events occurred in 4 patients (22.2%). The low rates of acute toxicity of this experience encourages considering MRgSBRT a feasibile therapeutic approach for the treatment of clinically relapsed PC. Accurate gating of target volumes, the online adaptive planning workflow and the high definition of MRI treatment images allow delivering high doses to the PTV while efficiently sparing organs at risk (OARs).
Identifiants
pubmed: 37218005
doi: 10.1186/s13014-023-02271-y
pii: 10.1186/s13014-023-02271-y
pmc: PMC10201772
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
84Informations de copyright
© 2023. The Author(s).
Références
Radiother Oncol. 2018 Mar;126(3):519-526
pubmed: 29277446
Int J Radiat Oncol Biol Phys. 2020 Feb 1;106(2):291-299
pubmed: 31629838
Urol Oncol. 2014 Jul;32(5):701-6
pubmed: 24629499
Eur Urol Oncol. 2021 Aug;4(4):628-634
pubmed: 32536573
J Appl Clin Med Phys. 2016 Nov 08;17(6):107-117
pubmed: 27929486
Adv Radiat Oncol. 2020 May 12;5(5):965-977
pubmed: 33083660
Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):976-985
pubmed: 28209443
Strahlenther Onkol. 2019 Mar;195(3):193-198
pubmed: 30649567
Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1086-1094
pubmed: 31419510
Clin Transl Radiat Oncol. 2019 Apr 08;18:98-101
pubmed: 31341983
Eur Urol. 2021 Feb;79(2):243-262
pubmed: 33172724
Urologia. 2022 Feb;89(1):5-15
pubmed: 34496707
Front Oncol. 2021 Apr 01;11:616027
pubmed: 33869001
Front Oncol. 2022 Apr 13;12:858740
pubmed: 35494082
Radiat Oncol. 2019 Jun 3;14(1):92
pubmed: 31167658
Clin Oncol (R Coll Radiol). 2018 Feb;30(2):93-100
pubmed: 29208480
Cancer Radiother. 2014 Oct;18(5-6):524-34
pubmed: 25192626
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Life (Basel). 2022 Oct 28;12(11):
pubmed: 36362882
Technol Cancer Res Treat. 2012 Dec;11(6):591-7
pubmed: 22568625
World J Urol. 2016 Mar;34(3):311-7
pubmed: 26062525
Cancer Treat Rev. 2021 Apr;95:102176
pubmed: 33743409
Eur Urol Focus. 2016 Jun;2(2):158-171
pubmed: 28723532
Semin Radiat Oncol. 2013 Jul;23(3):222-34
pubmed: 23763889
Strahlenther Onkol. 2020 Jan;196(1):1-14
pubmed: 31586232
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Eur Urol. 2021 Feb;79(2):263-282
pubmed: 33039206
Strahlenther Onkol. 2017 Sep;193(9):683-691
pubmed: 28623436
Semin Radiat Oncol. 2000 Jul;10(3):200-9
pubmed: 11034631
Eur Urol. 2012 Jun;61(6):1204-11
pubmed: 22421081
Cancers (Basel). 2022 Jun 29;14(13):
pubmed: 35804958
Front Oncol. 2021 Sep 09;11:681448
pubmed: 34568012
Pract Radiat Oncol. 2015 Nov-Dec;5(6):e615-23
pubmed: 26059509
Ann Oncol. 2020 Sep;31(9):1119-1134
pubmed: 32593798
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
pubmed: 16798415
Radiat Oncol. 2020 Mar 23;15(1):69
pubmed: 32248826
Int J Clin Oncol. 2004 Dec;9 Suppl 3:1-82
pubmed: 15818867
Cancers (Basel). 2021 Jan 06;13(2):
pubmed: 33419144
Cancer. 2007 Oct 1;110(7):1417-28
pubmed: 17694553
Head Neck. 2020 Sep;42(9):2473-2485
pubmed: 32437021
Adv Radiat Oncol. 2021 Jul 01;6(5):100748
pubmed: 34646967
Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):614-621
pubmed: 30825495
Eur Urol. 2021 Sep;80(3):280-292
pubmed: 33309278
Br J Radiol. 2019 Feb;92(1094):20180494
pubmed: 30379566
Crit Rev Oncol Hematol. 2021 Nov;167:103500
pubmed: 34688894
Tumori. 2010 Jan-Feb;96(1):71-5
pubmed: 20437861
Lancet Oncol. 2017 Nov;18(11):e633
pubmed: 29208387
Radiother Oncol. 2021 Jun;159:146-154
pubmed: 33775715
Eur Urol. 2012 May;61(5):961-71
pubmed: 22280856
Clin Oncol (R Coll Radiol). 2020 Nov;32(11):688-703
pubmed: 32893056
Radiat Oncol. 2017 Mar 9;12(1):49
pubmed: 28274241
Eur Urol Oncol. 2020 Apr;3(2):183-197
pubmed: 31411996
J Clin Oncol. 2020 Jun 10;38(17):1963-1996
pubmed: 31940221
Phys Imaging Radiat Oncol. 2021 Jun 07;18:78-81
pubmed: 34258412